Cadian Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Cadian Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-31,956	Closed	-$1.62M	–	50
2016 Q3	$1.62M	Sell	31,956 -272,926	-90%	-$13.6M	0.09%	48
2016 Q2	$13.9M	Buy	304,882 +20,000	+7%	+$921K	0.76%	31
2016 Q1	$11.3M	Sell	284,882 -214,990	-43%	-$8.53M	0.76%	30
2015 Q4	$28.3M	Buy	499,872 +139,475	+39%	+$7.09M	1.02%	27
2015 Q3	$14.3M	Buy	360,397 +260,000	+259%	+$12.6M	0.52%	52
2015 Q2	$4.79M	Buy	+100,397	New	+$4.26M	0.14%	68

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cadian Capital Management's NBIX Position: Q4 2016 in Review

Cadian Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2016, closing a stake of 31,956 shares — an estimated $1.62M sold.

Cadian Capital Management first reported a position in NBIX in Q2 2015 and held it in 6 quarters. The position peaked at $28.3M in Q4 2015. 225 funds tracked by Wall St. Rank hold NBIX as of Q4 2016.

Cadian Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2016 after selling out during the quarter.
Cadian Capital Management sold 31,956 Neurocrine Biosciences shares in Q4 2016, an estimated $1.62M.
Cadian Capital Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 6 quarters.
Cadian Capital Management's Neurocrine Biosciences position peaked at $28.3M in Q4 2015.
225 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2016.

Based on Cadian Capital Management's 13F filing for Q4 2016, filed 13 Feb 2017.